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ABSTRACT 
Background: International guidelines recommend simple spirometry for bronchiectasis 
patients. However, pulmonary pathophysiology of bronchiectasis is very complex and still 
poorly understood. Our objective was to characterize lung function in bronchiectasis and 
identify specific functional sub-groups. 
Methods: This was a multicenter, prospective, observational study enrolling consecutive 
adults with bronchiectasis during stable sate. Patients underwent body-plethysmography 
before and after acute bronchodilation testing, diffusing lung capacity (DLCO) with a 3-year 
follow up. Air trapping and hyperinflation were a residual volume (RV)>120%predicted and 
a total lung capacity>120%predicted. Acute reversibility was: ΔFEV1 ≥12% and 200 ml 
from baseline (FEV1rev) and ΔRV ≥10% reduction from baseline (RVrev). Sensitivity 
analyses included different reversibility cutoffs and excluded patients with concomitant 
asthma or chronic obstructive pulmonary disease.  
Results: 187 patients were enrolled (median age: 68 years; 29.4% males). 
Pathophysiological abnormalities often overlapped and were distributed as follows: air 
trapping (70.2%), impaired DLCO (55.7%), airflow obstruction (41.1%), hyperinflation 
(15.7%) and restriction (8.0%). 9.7% of patients had normal lung function. RVrev (17.6%) 
was more frequent than FEV1rev (4.3%). Similar proportions were found after multiple 
sensitivity analyses. Compared with non-reversible patients, patients with RVrev had more 
severe obstruction (mean(SD) FEV1%pred: 83.0% (24.4) vs 68.9% (26.2); P=0.02) and air 
trapping (RV%pred, 151.9% (26.6) vs 166.2% (39.9); P=0.028). 
Conclusions: Spirometry alone does not encompass the variety of pathophysiological 
characteristics in bronchiectasis. Air trapping and diffusion impairment, not airflow 
obstruction, represent the most common functional abnormalities. RVrev is related to worse 
lung function and might be considered in bronchiectasis’ workup and for patients’ 
functional stratification.  
INTRODUCTION 
1Bronchiectasis is characterized by irreversibly damaged and dilated bronchi in the context 
of recurrent respiratory symptoms, such as productive cough, and episodes of infective 
exacerbations [1]. Lung function abnormalities in bronchiectasis patients are usually 
ascribed to the extent and severity of bronchial derangement as well as the presence of 
other predisposing factors, including smoking status or the co-existence of other 
respiratory diseases, such as asthma or chronic obstructive pulmonary disease (COPD). 
In 1952 Whitwell suggested that the development of bronchiectasis is promoted by an 
early involvement of lymphoid follicles in small airways, which gradually leads to the 
obstruction of more distal airways [2]. Accordingly, bronchiectasis has been always 
described as a chronic obstructive disease in most of the medical textbooks and the forced 
expiratory volume in one second (FEV1) has been employed to evaluate functional 
impairment in both daily practice and clinical research [3,4]. Furthermore, the FEV1 has 
been included in both severity scores, the Bronchiectasis Severity Index and the FACED 
score, recently developed and validated for their use in bronchiectasis patients [5,6].  
The 2010 British Thoracic Society (BTS) guidelines recommend simple spirometry to 
investigate functional abnormalities in adults with bronchiectasis, leaving the measurement 
of lung volumes and gas transfer factor (KCO) only in specific cases of airflow obstruction 
such as COPD or emphysema [7]. However, recent literature suggested that 
bronchiectasis patients might show a variety of pathophysiological abnormalities, including 
restrictive or mixed patterns, isolated air trapping or even normal lung function [8-11]. 
Moreover, functional measurements other than FEV1, such as the degree of hyperinflation 
                                                        
Abbreviations: ATS = American Thoracic Society; COPD = chronic obstructive pulmonary disease; DLCO = lung 
diffusion capacity; ERS = European Respiratory Society; FEV1 = Forced Expiratory Volume in 1 second; FEV1/VC 
= Tiffeneau index; FRC = functional residual capacity; IC = inspiratory Capacity; ICS = inhaled corticosteroids; 
LABA = long acting beta-2 agonists; LAMA = long acting muscarinic antagonists; LLN = lower limit of normal; RV 
= Residual Volume; sRaw = total specific airway resistances; TLC = total lung capacity; VA = alveolar volume; VC 
= slow vital capacity 
and lung diffusion capacity, seem to be independent predictors of mortality [12]. Notably, 
although distal airways proved to be crucial in the genesis of obstruction in bronchiectasis, 
responsiveness to bronchodilators has always been evaluated considering improvements 
in FEV1 [13-15], which represents a rough indicator of small airways response in chronic 
obstructive diseases [16,17]. On the contrary, acute changes in static volumes and airway 
resistances demonstrated a higher sensitivity as markers of bronchodilation and have a 
close association with symptoms [16-20]. In light of these clinical and research gaps, we 
designed a multicenter epidemiological prospective study with the following objectives: the 
primary aim was to investigate the different pulmonary pathophysiological characteristics 
in adults with bronchiectasis according to a comprehensive evaluation of plethysmography 
and lung diffusion capacity (DLCO); secondary aims were to explore the presence and role 
of air trapping reversibility and to identify different functional sub-groups in patients with 
bronchiectasis.  
Some of the results of this study have been previously reported in the form of an abstract 
[21]. 
 
MATERIALS AND METHODS 
 
Study design 
This was a multicenter, prospective, observational study of adult outpatients attending the 
bronchiectasis outpatient clinic at the IRCCS Fondazione Ca’ Granda Ospedale Maggiore 
Policlinico in Milan and the San Gerardo Hospital in Monza, Italy, from January 2013 to 
December 2014. Standard operating procedures for the outpatient care of bronchiectasis 
patients in both centers included the assessment of body-plethysmography before and 
after the bronchodilation test, together with DLCO. Consecutive patients aged ≥18 years 
with clinically significant bronchiectasis diagnosed on high-resolution computed 
tomography (HRCT) scan in stable state were recruited. Inclusion criteria were: a) a 
clinical history consistent with bronchiectasis (cough, chronic sputum production and/or 
recurrent respiratory infections); b) at least one chest HRCT demonstrating bronchiectasis 
affecting one or more lobes; c) clinical stability, defined as the absence of hospitalization 
or bronchiectasis exacerbations that required use of systemic corticosteroids or antibiotics 
up to 3 months before the study enrollment. Exclusion criteria were the following: a) 
inability to give the inform consent; b) inability to perform repeatable lung function 
maneuvers; c) a confirmed diagnosis of cystic fibrosis; d) traction bronchiectasis in a 
context of pulmonary fibrosis; e) pregnancy at the time of recruitment; f) history of drug 
abuse; g) impaired cognitive function (Mini-Mental State Examination score <26) or 
psychiatric illness; h) known unstable arrhythmia. 
This study was conducted in accordance with the amended Declaration of Helsinki and it 
was reviewed and approved by the Ethical Committees of both hospitals. Each recruited 
patient gave a written, informed consent.  
 
Data collection and microbiological analysis 
At the time of enrollment, all patients underwent the same comprehensive diagnostic work-
up as recommended by the 2010 BTS guidelines [7]. Demographics, comorbidities, 
disease severity, respiratory symptoms, microbiology, radiological, and laboratory findings 
in stable state, long-term treatments and outcomes (including exacerbations, 
hospitalizations, and mortality) during a three-year follow-up were recorded. Etiology of 
bronchiectasis was evaluated as previously described [22]. Disease severity was 
evaluated through the BSI [5]. Details on radiological and clinical scoring are reported in 
the data supplement. 
 
Pulmonary function tests 
Lung function tests were performed according to current American Thoracic Society (ATS) 
/ European Respiratory Society (ERS) recommendations [18,23,24]. Static, dynamic lung 
volumes and total specific airway resistances were assessed by means of a constant-
volume body plethysmograph (PowerCube-Body Box; Ganshorn Medizin Electronic; 
Niederlauer, Germany). Airflow obstruction and a restrictive ventilatory defect were defined 
according to lower limit of normal (LLN) criteria [18]. ATS/ERS criteria were adopted to 
grade obstruction severity [18].  A mixed obstructive-restrictive pattern was considered as 
the concomitant presence of a FEV1/ slow vital capacity (VC)<LLN and a total lung 
capacity (TLC)<LLN [18]. The presence of air trapping was defined as a residual volume 
(RV)>120%predicted value [16,25]. Hyperinflation was defined as a TLC>120%predicted 
value [26]. Bronchodilation responsiveness was assessed according to the latest 
recommendations [18] and was tested both in terms of reversibility of FEV1 and RV. 
Briefly, plethysmographic measurements were repeated 15 minutes after administration of 
4 doses of salbutamol metered dose inhaler 100 mcg with a spacer applied. Due to the 
lack of consensus, different cutoff levels were applied in two different subsets of patients: 
1) patients with airflow obstruction, considering a significant airflow reversibility: a) an 
increase in FEV1 ≥12% and ≥200 mL from the baseline value [18] and b) an increase of 
≥400 mL from the baseline value as suggested by the British Thoracic Society/Scottish 
Intercollegiate Guidelines Network (BTS/SIGN) guidelines [27]; 2) patients with air 
trapping, in which a significant air trapping reversibility was considered as: a) a decrease 
in RV ≥ 10% from the baseline value or b) an absolute reduction of ≥300 mL from the 
baseline value as previously suggested [17,28]. Lung diffusion capacity for carbon 
monoxide (DLCO), KCO and alveolar volume (VA) were measured with the single breath 
maneuver (GA2002CO, Ganshorn Medizin Electronic; Niederlauer, Germany), assessing 
the VA by means of the inert gas dilution technique [24]. For every patient, the VA 
measurements were normalized with plethysmographic TLC as suggested by Hughes et al 
[29]. The presence of ventilation inhomogeneity was considered as a VA/TLC <0.8 
according to Santus et al [30] and Neder et al [31]. All bronchodilators and/or inhaled 
corticosteroids (ICS) were withdrawn 24 hours before the lung function testing. According 
to the standard operating procedures, all patients were asked to perform pulmonary 
physiotherapy before performing pulmonary function testing. During follow up, patients 
continued their chronic bronchodilator/anti-inflammatory treatment based on normal clinical 
practice and on the clinical judgment of the attending physician that was blind to the scope 
of the study. 
 
Functional stratification and sub-groups 
A functional stratification was postulated a priori to define different pathophysiological 
entities associated with bronchiectasis. To identify the bronchiectasis sub-groups, four 
main criteria were adopted and sequentially applied: presence of 1) air trapping, 2) airflow 
obstruction, 3) acute bronchodilator reversibility if criteria 1 and 2 were present, and 4) 
restriction. Patients, thus, had to fall within the following sub-groups: A) normal 
plethysmography, B) acutely non-reversible obstruction – i.e. non-reversible air trapping or 
airflow obstruction, C) reversible air trapping, D) reversible airflow, E) restriction and, in 
case restriction co-existed with the characteristics of group B, C and D, the resulting sub-
group was considered having a F) mixed functional abnormality. More details on functional 
sub-groups is provided in the online data supplement.  
 
Study outcomes 
All-cause mortality was analysed as primary outcome and defined as death for any cause 
from the first visit to completion of a 3-year follow-up. Secondary outcomes included 
exacerbations and three year all-cause mortality. For a detailed definition of exacerbation, 
please see the online supplement. Severe exacerbations were defined as unscheduled 
hospitalizations or emergency department visits for severe bronchiectasis exacerbations or 
complications and were recorded from patient histories and verified using administrative 
databases, according to the BTS guidelines [7]. 
Statistical analysis 
Data were analyzed with SPSS 21.0 for Windows 10 (SPSS Inc., Chicago, IL, USA). 
Predicted normal lung function values were from Quanjer [32]. For consistency reasons, in 
the present study the Global Lung Function Initiative 2012 predictive equations [33] were 
not adopted, considered the unavailability of predictive equations for VC (here used for the 
definition of airflow obstruction) and all the plethysmographic parameters. Continuous 
variables are expressed as median (interquartile range – IQR) or means (standard 
deviation - SD), according to their parametric distribution assessed with the Shapiro-Wilk 
test. Comparisons between groups were performed by means of Kruskal Wallis test, 
ANOVA, Mann-U-Whitney or unpaired t-test as appropriate. The model included effects for 
period, carryover, treatment, time and the interaction of treatment and time and a random 
subject effect. Linear regressions were computed with the least mean square method. 
Tests were two-sided and statistical significance was taken at p<0.05.  
Sensitivity analysis 
To investigate whether the coexistence of COPD or asthma could represent a confounding 
factor that would impact on the distribution and classification of lung function parameters, 
the primary analyses were repeated excluding patients with a concomitant diagnosis of 
asthma or COPD. Furthermore, to assess the possible centre-related difference in the 
prevalence of lung function abnormalities, patients were also divided in the two cohorts of 
provenience and thus analysed accordingly. 
 
RESULTS 
 
Study sample 
A total of 187 patients were enrolled, 63 patients from Milan and 124 from Monza, (median 
[IQR] age: 68 [59-73] years; 29.4% males). Anthropometric and clinical variables are 
presented in Table 1 and Table 2. Forty (42.2%) patients were either actual or former 
smokers and the most common comorbidities were gastroesophageal reflux disease 
(20.8%), COPD (18.7%) and asthma (12.3%). More than one third of the patients were 
chronically infected with at least one microorganism, and 22.5% had chronic 
Pseudomonas aeruginosa infection. A total of 88 (48.5%) patients were exposed to long-
term bronchodilator therapy, and 52 out of 88 (59.1%) were treated with an ICS either in 
fixed dose combination or alone.  
 
Functional characteristics in bronchiectasis 
A summary of the pathophysiological characteristics of the study sample is shown in 
Figure 1. 58.9% of patients had a normal spirometry. 9.7% had both normal spirometry 
and plethysmography (Figure 1). Taking into account also plethysmography and DLCO, the 
most frequently observed functional abnormality was air trapping (70.2%), followed by a 
reduction in DLCO (55.7%), airflow obstruction (41.1%), hyperinflation (15.7%) and a 
restrictive ventilatory defect (8.0%) (Figure 1). Patients had often overlapping features, 
with 23.0% of the study sample having concomitantly airflow obstruction, air trapping and a 
DLCO impairment, while 16.6% had air trapping and a reduced DLCO (Figure 2). 
Hyperinflation was always associated with air trapping, with a mean(SD) RV/TLC of 
130.5%pred (27.9%). 51.9% of patients with air trapping had a FEV1/VC within normal 
values. A pure restrictive disease was found in only 5.5% of patients. Only two patients 
had isolated airflow obstruction, but isolated air trapping or an impaired DLCO were found 
in 15.5% and 11.6% of patients, respectively (Figure 2).  
 
Airflow and air trapping reversibility to salbutamol 
Overall, 137 (73.3%) patients underwent bronchodilation testing (Figure 3, Panel A). 
Significant reversibility of air trapping was found in 33 (17.6%) patients (26.4% of patients 
tested for reversibility) (Figure 3, Panel B). With the 300 ml reversibility cut-off for RV, 
patients with reversible air trapping were 25 (13.4%). Reversibility of airflow obstruction 
according to ATS/ERS criteria was found in 4 (3.2%) patients (5.7% of tested) while no 
patients satisfied the BTS/SIGN criterion [27] for airflow reversibility (Figure S1). Only one 
patient presented both airflow and air trapping reversibility and was considered as having 
reversible airflow obstruction (Figure 3, Panel B). 
 
Functional sub-groups in bronchiectasis 
The functional sub-groups identified with the four-step methodology are reported in Figure 
4. Accordingly, 39 (20.8%) were classified in sub-group A (normal plethysmography), 91 
(48.6%) in sub-group B (acutely non-reversible obstruction), 33 (17.6%) in sub-group C 
(reversible air trapping), 8 (4.3%) in sub-group D (reversible airflow) and 11 (5.9%) in sub-
group E (restricted). Only patients characterised by reversible airflow showed signs of 
ventilation inhomogeneity at DLCO (Figure 4). Patients’ distribution following alternative 
criteria for bronchodilator responsiveness are detailed in the data supplement and in 
Figure S1. 
 
Sensitivity analysis 
The primary sensitivity analysis excluded a total of 54 patients: 34 with COPD, 17 with 
asthma and 3 with both asthma and COPD. The proportion of patients tested for 
reversibility did not change compared with the whole sample (73.5% vs. 74.2%). The 
distribution of pathophysiological abnormalities and the proportion of the functional sub-
groups did not change significantly compared to the whole study sample (data supplement 
and Figure S2). Particularly, the number of patients with positive reversibility to air trapping 
was comparable (15.0% vs. 17.6%, P = 0.421), as was the proportion of hyperinflated 
patients (15.6% vs. 15.7%, P ≈ 1.000) (Figure 2).  
The secondary sensitivity analysis was carried out considering separately patients coming 
from the Milan and the Monza cohort. Compared with the whole study sample, no 
significant changes were found in the prevalence of lung function abnormalities and air 
trapping reversibility (Figure S3). Furthermore, according to the four-step functional 
algorithm, the proportion of each functional sub-group did not change when the largest 
cohort (Monza) was assessed (Figure S4 and online supplement). Taking in account the 
small changes provided by the sensitivity analyses, the univariate analysis was carried out 
in the whole study sample (N = 187). 
 
Sub-group analysis 
The comparison of baseline characteristics of functional sub-groups is presented in Table 
3 and 4. As sub-groups D, E and F were the less numerically represented, they were not 
included in the main analysis. As expected, compared with groups B and C, group A had 
the best lung function. Compared with group B, group C had worse airflow obstruction 
(mean %predicted [SD] FEV1: 68.9 [26.2] vs. 83.0 [24.4], P=0.02) and higher RV (166.2 
[39.9] vs. 151.9 [26.6], P=0.028) and worse (median%predicted [IQR]) RV/TLC (130.4% 
[117.8-143.5] vs. 148.0 [121.3-156.9], P=0.029). Conversely, DLCO tended to be higher in 
group C, with progressively lower values from group B to A. In average, DLCO was reduced 
due to a prevalent reduction in KCO (Table 3). No difference was observed in terms of 
HRCT scores, colonizing bacteria and BSI (Table 4). A trend towards a higher frequency 
of exacerbations per year of follow up from group A to group C was observed (ANOVA 
P=0.161), but no difference between groups in three-year mortality (Table 4).  
A univariate analysis including also sub-groups D, E and F is reported in Table S1.  
 
DISCUSSION 
 
The major findings of the presents study can be summarised as follows: 1) Among adults 
with bronchiectasis, the majority of functional abnormalities is missed when the 
assessment is limited to simple spirometry; 2) Air trapping and DLCO  impairment are the 
most common lung function abnormalities (70.2% and 55.7%, respectively); 3) 
Reversibility of residual volume is present in more than one fourth of bronchiectasis 
patients with air trapping, while FEV1 reversibility is less frequently observed; 4) 
Dichotomous lung function criteria can be adopted to identify and divide bronchiectasis in 
specific pathophysiological patterns. 
To our knowledge, this is the first study showing a comprehensive functional assessment 
in adults with bronchiectasis, including plethysmography, DLCO and lung volume 
reversibility. In 49.2% of patients, plethysmographic and DLCO assessment detected lung 
function abnormalities that would have been missed with the sole spirometry, while only 
9.7% of patients had no functional alterations at all. These data underline the need for a 
standardized comprehensive functional approach to identify pathophysiological features 
such as air trapping or impaired diffusing capacity that are common in bronchiectasis [12]. 
A series of radiological studies demonstrated that the major determinants of airflow 
obstruction and its decline over time were represented by signs of bronchiolitis and small 
airway disease, such as bronchial wall thickness and decreased attenuation on the 
expiratory CT [9,34]. Considering the significant role of small airways in bronchiectasis 
[34,35], a simple approach limited to spirometry is not sufficient to detect hyperinflation 
and increased airway resistances, the presence of which may imply regional flow 
limitation, lung inhomogeneity and non-uniform distribution of closing pressures [16,36]. 
More recently, the lung clearance index (LCI) has been reported to be a non-invasive, 
reliable and reproducible method to investigate lung ventilation inhomogeneity in patients 
with stable non-cystic fibrosis bronchiectasis [37]; however LCI, unlike traditional lung 
function parameters, was found to be less sensitive to exacerbations or external 
interventions [38].  
In the present study, DLCO was uniformly impaired across the studied sample, and despite 
being an important factor for patients’ outcomes [12], its relation with other functional 
variables in the natural history of bronchiectasis still represents an unsolved question. 
Airway hyper-reactivity [39] and airflow reversibility have often been considered common 
in bronchiectasis, the latter ranging from 14% to 25% according to different studies 
[14,15,40]. Our findings are in line with those of Aksamit and colleagues [40] who recently 
found a significant acute bronchodilator response in terms of FEV1 in 5% of cases out of a 
cohort of 963 bronchiectasis patients. Although the majority of patients with obstructive 
diseases such as COPD are defined as non-responsive with spirometry criteria, they can 
show important reductions in static volumes following administration of bronchodilators; 
such improvements, as opposed to changes in FEV1, are significantly related with changes 
in dyspnoea and exercise tolerance [16,20,41]. In the present study we demonstrated that 
volume responsiveness occurs also in bronchiectasis, involving almost a third of the tested 
patients. Moreover, patients with reversible air trapping had more severe obstruction and 
higher baseline residual volume compared to non-reversible patients. This is in line with 
previous reports that studied FEV1 reversibility both in bronchiectasis and COPD [15,16]. A 
low FEV1 is associated with bronchiectasis exacerbations [42], however it remains unclear 
if the worsening of respiratory symptoms during these events is related to an acute further 
reduction in FEV1 or could be due to an increase in air trapping. To date, only one study 
investigated the association of bronchodilator response and bronchiectasis exacerbations, 
with inconclusive results [14]. Although limited in number, previous data showed that the 
association with asthma or COPD in patients with bronchiectasis has a great impact on 
patient related outcomes and translates in a difficult-to-control disease and more severe 
exacerbations [11,43,44]. However, the sensitivity analysis we performed confirmed that 
not only reversibility of air trapping is independent of the presence of other chronic 
obstructive diseases, but also that hyperinflation and air trapping are proper characteristics 
of bronchiectasis, indicating a pathological process involving both functional small airways 
disease and a loss of elastic recoil. 
Small airways hyper-reactivity is related to bronchial inflammation and neutrophil-driven 
inflammation is associated with disease severity in bronchiectasis [45,46]. The recent 
identification of peripheral neutrophil elastase activity as a predictor of exacerbations and 
lung function decline in bronchiectasis [47] and the correlation we found with reversibility of 
air trapping and worse lung function further support the hypothesis that in bronchiectasis 
patients bronchial hyper-reactivity may be a hallmark of disease severity and may help to 
identify more fragile patients.  
Notably, none of the functional sub-groups we identified differed in the chronic 
bronchodilator treatment. When, how and what kind of patients with bronchiectasis may 
benefit from bronchodilators or ICS therapy represents, so far, an unsolved issue. In the 
present study, the lack of difference in exacerbation rates between sub-groups may have 
been masked by not functionally-driven inhaled therapeutic approaches. Recent reviews 
and international guidelines report only very weak suggestions for long-term use of LABA 
or ICS in bronchiectasis [7,48,49]. Nonetheless in our study 30.8% of patients with normal 
plethysmography was exposed to inhaled bronchodilators or ICS and 20.5% to ICS only. 
The synergy demonstrated between long acting bronchodilators and ICS and their role as 
modulators of the production of superoxide anions and leukotriene-B4 in neutrophilic 
inflammation [50,51] should represent an additional incentive for setting specifically 
designed randomized controlled trials in patients with bronchiectasis.  
Some consideration should be made concerning the pragmatic approach we propose for 
the functional stratification of bronchiectasis patients. As it was previously shown, the 
degree of FEV1 responsiveness to bronchodilators can vary over time [52] and during 
exposure to chronic inhaled treatment [15,52], and this might be true also for reversibility 
of air trapping. Moreover, we suggest that methacholine challenge should be performed in 
all patients with normal plethysmography at baseline but that symptoms compatible with 
bronchial hyper-reactivity.  
The present pilot study is limited by the small sample size; this might be responsible for a 
limited representation of some functional patterns as patients with FEV1 reversibility. The 
threshold of 10% chosen for the air trapping reversibility relies on data published in 
literature [17,28] as no consensus has been defined so far. The duration of the follow up 
period and the sample size didn’t allow for further speculation on the role of air trapping 
responsiveness on exacerbations and mortality. Furthermore, the role of air trapping 
reversibility in patients without air trapping at baseline needs further investigation.  
In conclusion, spirometry alone does not encompass the variety of pathophysiological 
characteristics in bronchiectasis. Plethysmography, DLCO and reversibility testing are 
necessary for the definition and recognition of overlapping functional features in patients 
with bronchiectasis; waiting for larger randomized clinical trials on this topic, this functional 
assessment should lead to an individualized bronchodilator treatment and allow for an 
appropriate follow up. 
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TABLES 
Table 1. Demographics, comorbidities and chronic treatment of the study population. 
Variables Study group 
n. 187 
Demographics  
     Median (IQR) age, years 68 (59-73) 
     Either smokers or former smokers, n (%) 79 (42.2) 
Comorbidity  
     GERD, n (%) 39 (20.8) 
     COPD, n (%) 34* (16.6) 
     Asthma, n (%) 23* (12.3) 
     Connective tissue disease, n (%) 21 (11.2) 
     Myocardial infarction, n (%) 7 (3.7) 
     Peripheral vascular disease, n (%) 5 (2.7) 
     Moderate-severe liver disease, n (%) 5 (2.7) 
     Moderate-severe chronic kidney disease, n (%) 5 (2.7) 
     Congestive heart failure, n (%) 4 (2.1) 
     Mild liver disease, n (%) 2 (1.1) 
     Cerebrovascular accident, n (%) 1 (0.5) 
     Leukemia, n (%) 2 (1.1) 
Treatment  
     Macrolide, n (%) 14 (7.5) 
     Inhaled antibiotic treatment, n (%) 7 (3.7) 
Chronic bronchodilator therapy  
    LABA, n (%) 6 (3.2) 
LAMA, n (%) 24 (12.8) 
LABA/LAMA FDC or LAMA + LABA, n (%) 6 (3.2) 
ICS, n (%) 6 (3.2) 
LABA/ICS FDC 13 (10.5) 
LABA/LAMA/ICS 33 (17.6) 
Theophylline, n (%) 3 (1.6) 
 
n: number; IQR: interquartile range 25-75; GERD: gastro-oesophageal reflux disease; 
COPD: chronic Obstructive Pulmonary Disease; LABA: long acting β-2 agonists; LAMA: 
long acting muscarinic agonists; ICS: inhaled corticosteroids; FDC: fixed dose 
combination; * = the prevalence reported refers to the single cases. Among patients  with 
COPD and asthma, 3 patients had a concomitant diagnosis of COPD and asthma (see 
results in the text). 
 
 
Table 2. Clinical, radiological and  microbiological status of the study population. 
Variables Study group 
n. 187 
Disease severity  
     Median (IQR) BSI score,  6 (4-9) 
     BSI score Risk Class, n (%) 
 
                                          Mild 
                                          Moderate 
                                          Severe 
38 (30.6) 
49 (39.5) 
37 (29.8) 
Radiological status  
     Median (IQR) Reiff score 6 (4-6) 
     Mean (SD) Bhalla score 18.6 (10.5) 
Clinical status  
     Chronic cough, n (%) 63 (33.7) 
     Daily Sputum, n (%) 114 (61.0) 
     Sputum colour, n (%) 
 
                            Mucous 
                            Mucous-Purulent 
                            Purulent 
 30 (24.2) 
 34 (27.4) 
 11 (5.9) 
     Haemoptysis, n (%) 31 (16.6) 
     MRC, median (IQR) 1 (0-1) 
     MRC 4-5, n (%) 17 (9.1) 
     Long-term oxygen therapy, n (%) 14 (7.5) 
     Median (IQR) exacerbations in the previous year 2 (1-3) 
     At least one hospitalization in the previous year, n (%) 41 (21.9) 
Microbiology 
 
     Chronic infection with at least one pathogen, n (%) 72 (38.5) 
     P. aeruginosa, n (%) 42 (22.5) 
     H. influenzae, n (%) 17 (9.1) 
     S. aureus, n (%) 15 (8.0) 
          MRSA, n (%) 3 (1.6) 
          MSSA, n (%) 12 (6.4) 
     K. pneumoniae, n (%) 7 (3.7) 
     S. pneumoniae, n (%) 4 (2.1) 
     Enterobacteriaceae, n (%) 2 (1.1) 
     Other bacteria, n (%) 2 (1.6) 
Patient related outcomes  
     Mean (SD) SGRQ 31.6 (20.2) 
     Median (IQR) one-year follow-up exacerbations 1 (0-2) 
     Median (IQR) three-year follow-up exacerbations 2 (0-4) 
     One-year mortality, n (%) 3 (1.6) 
     Three-year mortality, n (%) 7 (3.7) 
 
n: number; IQR: interquartile range 25-75; BSI: Bronchiectasis Severity Index; MRC: 
medical research council; FEV1: forced expiratory volume in the first second; MSSA: 
methicillin-sensitive Staphilococcus aureus; MRSA: methicillin-resistant Staphilococcus 
aureus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Lung function characteristics of the most represented functional groups identified 
by the lung function flow-chart. 
 
Normal 
plethysmography  
(A) 
Acutely non-
reversible 
obstruction (B) 
Reversible 
air trapping  
(C) P P 
 
N = 39, 20.8% N = 91, 48.6% N = 33, 17.6% 
 
(B) vs (C) 
Anthropometric   
    
Males (%) 12 (30.8) 24 (26.4) 7 (21.2) 0.956
b
 0.784
b
 
Age, years (IQR) 68.0 (58.5-73) 67.0 (60-73) 67.0 (57.5-74) 0.863
a
 0.801
d
 
BMI,  Kg/m
2
 (IQR) 25.9 (20.4-28.6) 22.8 (19.8-26.3) 23.4 (19.7-27.4) 0.163
a
 0.592
d
 
Lung function   
    
FEV1, %pred (SD) 94.7 (15.7) 83.0 (24.4) 68.9 (26.2) 0.001
c
 0.020
e
 
FEV1<50%pred, n (%) 0 (0.0) 9 (9.9) 9 (27.3) <0.001
b
 <0.001
b
 
FEV1<35%ped, n (%) 0 (0.0) 5 (5.5) 3 (9.1) 0.149
b
 0.954
b
 
VC, %pred (SD) 88.8 (15.6) 86.5 (20.0) 78.5 (21.6) 0.240
c
 0.128
e
 
FEV1/VC, %pred (IQR) 101.0 (96.2-107.0) 91.8 (79.0-97.6) 85.1 (76.2-92.2) <0.001
a
 0.047
d
 
Obstructed, n (%) 0 (0)  51 (56.0) 21 (63.6) <0.001 0.129
b
 
sRaw, %pred (IQR) 107.8 (78.6-121.3) 144.0 (120.9-187.4) 193.7 (134.4-249.0) <0.001
a
 0.102
d
 
FRC, %pred (SD) 104.2 (11.1) 126.4 (12.3) 135.8 (9.6) <0,001
a
 0.041
e
 
TLC, %pred (SD) 97.6 (8.6) 112.1 (11.5) 111.8 (8.7) <0.001
c
 0.665
e
 
TLC>120%pred, n (%) 0 (0.0) 26 (23.7) 4 (12.1) 0.018
b
 0.289
b
 
RV, %pred (SD) 110.0 (8.7) 151.9 (26.6) 166.2 (39.9) <0.001
c
 0.033
e
 
RV>120%pred, n (%) 0 (0.0) 86 (94.5) 25 (75.7) <0.001
b
 0.014
b
 
RV/TLC, %pred (IQR) 109  (103.1-116.1) 130.4 (117.8-143.5) 148.0 (121.3-156.9) <0.001
a
 0.029
d
 
DLCO, %pred (SD) 70.7 (18.1) 72.3 (23.8) 77.2 (20.2) 0.906
c
 0.759
e
 
DLCO<80%pred, n (%) 20 (51.3) 60 (65.9) 19 (57.6) 0.496
b
 0.647
b
 
KCO, %pred (IQR) 56.2 (47.7-67.8) 54.6 (44.7-65.4) 65.6 (43.7-70.1) 0.531
a
 0.274
d
 
VA%, pred (SD) 94.3 (12.4) 100.7 (18.2) 94.8 (20.1) 0.467
c
 0.392
e
 
VA/TLC, %pred (IQR) 0.94 (0.89-0.99) 0.89 (0.81-0.99) 0.92 (0.67-0.94) 0.088
a
 0.558
d
 
      
 
Variables with standard deviation (SD) are presented as mean values; parameters with 
inter-quartile range (IQR) are presented as median values; %pred: percent predicted 
value; TLC: total lung capacity; FRC: functional residual capacity; DLCO: diffusing lung 
capacity for carbon monoxide; VA/TLC: alveolar volume to total lung capacity ratio; KCO: 
transfer factor; FVC: forced expiratory volume; VC: slow vital capacity; FEV1/VC: 
Tiffeneau index; RV: residual volume; RV/TLC: residual volume to total lung capacity ratio, 
sRaw: total specific airway resistances. For other abbreviations please see text. a Kruskal 
Wallis test; b Chi Squared test; c ANOVA; d Mann-U-Whitney test; e unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Clincal characteristics of the most represented functional groups identified by the 
lung function flow-chart. 
 
Normal 
plethysmography  
(A) 
Acutely non-
reversible 
obstruction (B) 
Reversible 
air trapping  
(C) P P 
 
N = 39, 20.8% N = 91, 48.6% N = 33, 17.6% 
 
(B) vs (C) 
Radiology and clinic   
    
Bhalla score (IQR) 13.7 (7.5-18.0) 17.2 (10.0-25.0) 17.5 (13.0-23.0) 0.171
a
 0.806
d
 
Reiff score (IQR) 4.7 (4-5.5) 5.4 (4.0-6.0) 5.7 (5.0-6.0) 0.129
a
 0.245
d
 
BSI (IQR) 5.4 (4.0-7.0) 6.1 (4.0-10.0) 6.5 (5.0-9.0) 0.474
a
 0.527
d
 
Colonized (any), n (%) 17 (43.6) 38 (41.7) 13 (39.4) 0.832
b
 0.594
b
 
P. aeruginosa, n (%) 8 (20.5) 19 (20.9) 7 (21.2) 0.892
b
 0.638
b
 
COPD, n (%) 5 (12.8) 17 (18.7) 5 (15.1) 0.800
b
 0.656
b
 
Asthma, n (%) 2 (5.1) 10 (11.0) 7 (21.2) 0.050
b
 0.072
b
 
GERD, n (%) 10 (25.6) 21 (19.1) 12 (36.3) 0.145
b
 0.048
b
 
Cough, n (%) 16 (41.0) 44 (40.0) 15 (45.5) 0.826
b
 0.697
b
 
Sputum, n (%) 20 (51.3) 55 (60.4) 21 (63.6) 0.253
b
 0.408
b
 
Smokers, n (%) 14 (35.9) 42 (46.1) 14 (42.4) 0.896
b
 0.539
b
 
Outcomes   
    
Exacerb/year, n (IQR) 0.3 (0.0-0.8) 0.5 (0.0-0.8) 0.8 (0.3-1.15) 0.148
a
 0.161
d
 
Three-year mortality, n (%) 0 (0) 4 (6.5) 1 (5.0) 0.552
b
 0.908
b
 
Bronchodilator therapy   
    
LABA, n (%) 1 (2.6) 3 (3.3) 2 (6.1) 0.597
b
 0.693
b
 
LAMA, n (%) 2 (5.1) 15 (16.5) 4 (12.1) 0.261
b
 0.772
b
 
LABA/LAMA, n (%) 1 (2.6) 3 (3.3) 2 (6.1) 0.597
b
 0.424
b
 
ICS, n (%) 2 (5.1) 3 (3.3) 0 (0.0) 0.403
b
 0.324
b
 
LABA/ICS, n (%) 4 (10.2) 14 (15.4) 4 (12.1) 0.814
b
 0.294
b
 
LABA/ICS + LAMA, n (%) 2 (5.1) 13 (14.3) 8 (24.2) 0.034
b
 0.153
b
 
ICS (any), n (%) 8 (20.5) 30 (33.0) 12 (36.4) 0.297
b
 0.127
b
 
Inh. therapy (any), n (%) 12 (30.8) 51 (56.0) 20 (60.6) 0.009
b
 0.135
b
 
      
 
Variables are presented as median values with inter-quartile range (IQR), if not otherwise 
reported. Colonized: patients colonized with any microorganism; P. aeruginosa: patients 
with chronic P. aeruginosa infection; inh. therapy: bronchodilator therapy; exacerb/year: 
median number of exacerbations per year during the follow up period; Mortality: number of 
patients deceased during the follow up period; LABA: long acting β2 agonists; LAMA: long 
acting muscarinic antagonists: ICS: inhaled corticosteroids. For other abbreviations please 
see text. b Chi Squared test; c ANOVA; d Mann-U-Whitney test; e unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE CAPTIONS 
Figure 1. Distribution of the main pathophysiological characteristics according to 
spirometry, plethysmography and DLCO measurements within the study population 
(N = 187). Striped areas represent the percentage of patients with normal spirometry 
within each group. The column in light blue indicates patients with spirometry, 
plethysmography and DLCO  within normal values. 
 
Figure 2. Descriptive analysis of 187 bronchiectasis patients based on data from 
spirometry, plethysmography and DLCO. For the definition of airflow obstruction, air 
trapping and restriction please see text. The percentage relative to the whole study 
population is reported in each area. FEV1: forced expiratory volume in the first second; VC: 
slow vital capacity; RV: residual volume.  
 
Figure 3. Distribution of patients tested with acute bronchodilation challenge 
whithin the study population (N = 187, Panel A) and prevalence of airflow and air 
trapping reversibility (striped areas) among tested patients (N = 137, Panel B). RV: 
residual volume; FEV1: forced expiratory volume in one second. 
 
Figure 4. Flow chart indicating the pathways suggested for the functional evaluation 
of patients with non-CF bronchiectasis. Four main steps are included. Air trapping is 
evaluated first. The second step is represented by the evaluation of airflow obstruction. 
The third step is reflects by the assessment of acute bronchodilation response, both in 
terms of volume (patients with air trapping) and in terms of FEV1 (in patients that show 
airflow obstruction, ATS/ERS criteria). In patients with air trapping that do not show any 
reversibility at the residual volume, airflow reversibility should always be assessed. If both 
are absent, the patients belongs to the “acutely non-reversible obstruction” group. Finally, 
the last step is represented by the evaluation of TLC. If a restrictive ventilatory defect is 
present, the patient has “mixed” functional characteristics. Different colors identify the 
component mainly responsible for the DLCO impairment. Dashed ovals are groups not 
found within our study sample but that can theoretically exist. Numbers and percentages in 
each frame represent patients and their proportion in respect to the whole study sample. 
Pts: patients; FEV1: forced expiratory volume in one second; RV: residual volume; TLC: 
total lung capacity; %pred: percent predicted value; DLCO: diffusing lung capacity; LLN: 
lower limit of normal. 
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